Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04626583 · ClinicalTrials.gov registry record · Phase 1
Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells
A Phase 1 study, sponsored by University of Illinois at Chicago.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT04626583 is a Phase 1 study that has completed, run by University of Illinois at Chicago. The registered enrollment target is 8 participants.
The verdict
NCT04626583, a Phase 1 study, has completed, sponsored by University of Illinois at Chicago.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary located at University of Illinois at Chicago. The study will use digital conjunctival and corneal photography and corneal Scheimpflug Imaging, densitometry, and pachymetry for assessment of safety and corneal wound healing.
Interventions
- BIOLOGICAL Allogeneic MSC
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2021-03-05 |
| Est. Completion | 2023-04-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04626583
The ClinicalTrials.gov registry entry for NCT04626583 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Illinois at Chicago, which has 430 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Allogeneic MSC is the first listed.
NCT04626583 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04626583 about?
NCT04626583 is a clinical study titled "Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells". This study is a longitudinal assessment using a classic dose-escalation study design to assess the safety and maximal tolerated dose (MTD) of locally delivered allogeneic mesenchymal stromal cells (MSC) for promoting corneal repair. The study will be conducted at Illinois Eye and Ear Infirmary locat...
What is the current status of trial NCT04626583?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2021-03-05. Estimated completion is 2023-04-21.
What interventions are being tested in trial NCT04626583?
The interventions under investigation include: Allogeneic MSC (BIOLOGICAL).
Who is sponsoring clinical trial NCT04626583?
This trial is sponsored by University of Illinois at Chicago, which has 430 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.